http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#Head http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#assertion http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#provenance http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#pubinfo http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00661 http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association http://www.w3.org/2000/01/rdf-schema#label verapamil hydrochloride tablets usp are indicated for the treatment of the following angina 1 angina at rest including vasospastic prinzmetal s variant angina unstable crescendo pre infarction angina 2 chronic stable angina classic effort associated angina arrhythmias 1 in association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and or atrial fibrillation see warnings accessory bypass tract 2 prophylaxis of repetitive paroxysmal supraventricular tachycardia essential hypertension verapamil hydrochloride tablets are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00661 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#provenance http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#pubinfo http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#sig http://purl.org/nanopub/x/hasSignature InwSx9tMn6zVifCMic48tPYTr5bZuvJCvIAJulD+AvvSomN8vr5mSv8HOwYeKU4o2N2xSPRryVyb6AmPLHlPrifWwvfboVmVOW4EYvbg93IDfSaUd1Ub4IUISnAzDegm4ANlB6YmLiXTBX1TO+tjjPEo397QVbHBcDc6ZXj7wnY= http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://purl.org/dc/terms/created 2021-06-13T16:30:18.944+02:00 http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAPnGSGnKdvH01mw8v1pO4xjzrxX9iUP3dQW4w_q0VHHM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs